Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations.
Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT.TB test at a rate of approximately 60 Euros per test.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
[email protected]
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
[email protected]
